IDEAYA Biosciences, Inc. expects to report $511.1 million in cash, cash equivalents, and marketable securities as of September 30, 2023, but the amount is subject to change. The company has also entered into an at-the-market program and sales agreement to offer and sell common stock up to $250.0 million.